77 results about "Retinol binding protein" patented technology

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein.

Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies.

The present invention relates to a method for diagnosing a subject's Alzheimer's disease state. The method involves providing a database containing information relating to protein expression levels associated and not associated with Alzheimer's disease. The database includes information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein. Information relating to proteins found in one or more cerebrospinal fluid samples from a subject is also provided and a database is used to analyze the information from the subject to diagnose the subject's Alzheimer's disease state. Also disclosed is a computer readable medium and a system, both useful in carrying out the present invention.

The invention provides a kit for measuring the content of retinol-binding protein in human serum and a preparation method thereof. Reagent R1 and reagent R2 are composed of 3:1 volume ratio, R1: 0.01% to 4% w / w emulsifier, 0.1% to 2% w / w sodium chloride, 0.05% to 2% w / w Sensitizer, 0.02% w / w preservative, 30-100mmol / L buffer. R2: 0.1%-0.5% w / w latex microparticles bound with anti-human retinol-binding protein antibody, 0.1%-1.0% w / w bovine serum albumin, 0.02%-2% w / w Tween 20, 0.02 %-2% w / w stabilizer 2, 0.02%-2% w / w protein protectant 2, 0.02% w / w preservative, 20-50 mmol / L buffer. The kit of the invention has wide linear range, good sensitivity and stability, and has good clinical application prospect.

The invention relates to a detection kit for a retinol binding protein. The interior of a detection kit body comprises reagents R1 and reagents R2, wherein the reagents R1 comprise a buffer solution, polyethylene glycol, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin; and the reagents R2 comprise a buffer solution, latex grains combined with retinol binding protein monoclonal antibodies, tween-20, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin. A sample and the reagents are mixed at a certain volume ratio and generate a series of reactions, and then a reactant is placed under a semi / full-automatic biochemical analyzer, and the speed of absorbance change in the position of a main wavelength of 340nm is detected, so that the concentration magnitude of the retinol binding protein is measured and calculated. The detection kit has the advantages of accuracy, stability and convenience.

The invention discloses a kit for determining retinol binding protein (RBP) content through a magnetic particle chemiluminiscence method. The kit comprises a calibrator, a quality controller, resistance reagents, a magnetic particle reagent and a light-emitting substrate; the resistance reagents are a retinol binding protein coated antibody labeled with fluorescein isothiocyanate and a retinol binding protein labeled antibody labeled with alkaline phosphatase; the magnetic particle reagent is a magnetic particle and goat antibody FITC connector. The chemiluminiscence technology and immune magnetic particles are combined, and an approximately homogeneous reaction system is provided; by the adoption of a one-step reaction pattern, detection sensitivity and precision are greatly improved, the detection range is expanded, reaction time is greatly shortened, less than 25 min is spent from sample addition to result detection, and the kit is obviously faster than a similar kit; multiple samples can be tested on fully-automatic chemiluminescence apparatus at the same time, high-flux rapid determination of retinol binding protein is realized, accuracy is high, specificity is high, and precision and detection efficiency are greatly improved.

The invention provides colloidal gold quick detection test paper of retinal binding protein (RBP) and an application thereof. The detection test paper comprises a test strip and a baseplate for supporting the test strip, wherein the test strip at least comprises a combining and releasing cushion and a detection cushion; retinal binding protein resistant monoclonal antibodies marked by colloidal gold are wrapped on the combining and releasing cushion in advance; and test lines of retinal binding protein resistant polyclonal antibodies are wrapped on the detection cushion in advance. The RBP detection test paper has low cost and easy preservation, has rapidness, convenience, high sensitivity and good accuracy when used for testing the retinal binding protein, is suitable for clinical and household use and has industrialization.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

The invention relates to a hybridoma cell capable of secreting an anti retinol binding protein monoclonal antibody, wherein the hybridoma cell has the preservation number of CCTCC No:C2013132. The hybridoma cell has high secreting yield, and the anti retinol binding protein monoclonal antibody obtained by secretion has the advantages of high affinity and high specificity, can be widely applied in the field of retinol binding protein detection, such as the detection reagent or detection equipment preparation fields and the like, and has significant advantages in specificity, sensitivity, detection rate and other aspects compared with a conventional detection method. In addition, the invention also relates to the monoclonal antibody secreted by the hybridoma cell, the hybridoma cell and an application of the monoclonal antibody.

The invention discloses a process for purifying a human retinol binding protein and a preparation process of a polyclonal antibody thereof. According to the invention, by using a separation technology by multiple chromatographic columns such as a DEAE-Sepharose Fast Flow (DEAE-S) ion exchange column, a molecular sieve (Superdex 75, Sephacryls-200) and a hydrophobic column Phenyl SepharoseTM High Performance (PHSP), the human retinol binding protein is successfully purified from urine of a patient suffering from renal injury, and the immunogenicity of the RBP protein is remained to the greatest degree. The obtained human RBP antigen is used for immunizing animals, thus obtaining a polyclonal antibody of the human retinol binding protein. The obtained polyclonal antibody of the human retinol binding protein can be applied to an immunonephelometry kit.